Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:0c3fb15a8e98a61d6f59c18778b09965]
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:0c3fb15a8e98a61d6f59c18778b09965]
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization.
Bio2RDF identifier
0c3fb15a8e98a61d6f59c18778b09965
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0c3fb15a8e98a61d6f59c18778b09965
measure [clinicaltrials_vocabulary:measure]
Change from Baseline in Develo ...... cose ≥ 200 mg/dL) at 12 months
time frame [clinicaltrials_vocabulary:time-frame]
0 to 12 month
description
To evaluate prevention effect ...... s after date of randomization.
identifier
clinicaltrials_resource:0c3fb15a8e98a61d6f59c18778b09965
title
Change from Baseline in Develo ...... dL) at 12 months 0 to 12 month
@en
type
label
Change from Baseline in Develo ...... fb15a8e98a61d6f59c18778b09965]
@en